Related Experiment Video
Updated: May 31, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy
Houman Ashrafian1, William J McKenna, Hugh Watkins
1Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom.
Insights
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder primarily affecting the sarcomere. Understanding its molecular basis reveals common pathways and potential therapeutic targets for this cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a well-characterized monogenic cardiovascular disorder.
- Genetic studies consistently identify the sarcomere as the primary site of HCM pathology.
- HCM is a leading cause of sudden cardiac death in young individuals.
Purpose of the Study:
- To review the molecular basis of hypertrophic cardiomyopathy (HCM).
- To elucidate the consequences of HCM-associated mutations.
- To highlight emerging therapeutic strategies targeting molecular defects in HCM.
Main Methods:
- Review of existing genetic and molecular studies on HCM.
- Analysis of biophysical consequences of myofilament mutations.
- Examination of the link between molecular defects and clinical manifestations.
Main Results:
- HCM mutations predominantly affect sarcomeric proteins, enhancing Ca(2+) sensitivity and force production.
- Molecular defects converge on energy deficiency and altered calcium handling.
- These lead to characteristic anatomical and functional changes in the heart, including hypertrophy and diastolic dysfunction.
Conclusions:
- HCM serves as a model for understanding Mendelian disorders at a molecular level.
- Targeting specific molecular pathways offers promising therapeutic avenues for HCM.
- Further research is needed to fully connect molecular mechanisms to clinical outcomes.
Abstract:
As described in earlier reviews in this series on the molecular basis of hypertrophic cardiomyopathy (HCM), HCM is one of the archetypal monogenic cardiovascular disorders to be understood at the molecular level. Twenty years after the discovery of the first HCM disease gene, genetic studies still confirm that HCM is principally a disease of the sarcomere. At the biophysical level, myofilament mutations generally enhance Ca(2+) sensitivity, maximal force production, and ATPase activity. These defects ultimately appear to converge on energy deficiency and altered Ca(2+) handling as major common paths leading to the anatomic (hypertrophy, myofiber disarray, and fibrosis) and functional features (pathological signaling and diastolic dysfunction) characteristic of HCM. In this review, we provide an account of the consequences of HCM mutations and describe how specifically targeting these molecular features has already yielded early promise for novel therapies for HCM. Although substantial efforts are still required to understand the molecular link between HCM mutations and their clinical consequences, HCM endures as an exemplar of how novel insights derived from molecular characterization of Mendelian disorders can inform the understanding of biological processes and translate into rational therapies.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Pharmacogenomics: Identification of New Drug Targets
01:29Heart Failure II: Pathophysiology
01:25Cardiomyopathy I: Introduction and Classification